中東およびアフリカの迷走神経刺激市場 – 2029 年までの業界動向と予測

中東およびアフリカの迷走神経刺激市場の分析と洞察

迷走神経は、代謝恒常性を調節する自律神経系の重要な構成要素であり、求心性および遠心性の経路を介して恒常性を維持する神経内分泌免疫軸の重要な構成要素として機能します。手動または電気刺激を含む迷走神経を刺激するあらゆるアプローチは、迷走神経刺激 (VNS) と呼ばれます。難治性てんかんおよび治療抵抗性うつ病の場合、左頸部 VNS は承認された治療法です。

WHO によると、神経疾患は世界中の全疾病の 4.5% ～ 11% を占めています。迷走神経刺激装置は、てんかん、うつ病、喘息、心血管疾患を患う患者の治療にも使用されています。

中東およびアフリカの迷走神経刺激市場は、2022年から2029年の予測期間に成長すると予想されています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に4.1％のCAGRで成長し、2021年の5,539万米ドルから2029年には7,613万米ドルに達すると分析しています。

市場定義: 中東およびアフリカの迷走神経刺激市場

迷走神経は、人の脳幹から首、胸部、腹部まで伸びる長い脳神経です。これは副交感神経系の一部で、人が休んでいる間に体の機能を調整するため、一般的に休息・消化系と呼ばれています。迷走神経は、消化器系や肺、心臓、肝臓などの臓器から人の脳にメッセージを送ります。消化、心拍数、呼吸数など、いくつかの臓器の機能を制御します。血管運動活動と反射神経を司ります。また、発声、気分、免疫も調整します。また、人の耳、副鼻腔、食道の感覚機能にも影響を及ぼします。

VNS では、胸部の皮膚の下にパルス ジェネレーターを挿入します。ペースメーカーに似たこの埋め込み型デバイスは、迷走神経を介して脳に定期的な電気パルスを送ります。パルス ジェネレーターの上に付属の磁石を置くことで、追加の刺激を与えることができます。呼吸法、ヨガ、投薬などのリラクゼーション テクニックは、迷走神経の活動に影響を与え、不安や気分関連の症状を和らげる効果を高めます。VNS は個人の身体的健康を改善し、てんかんやうつ病などのいくつかの症状に効果があります。この治療法は、リラクゼーションを促進し、炎症を軽減する効果があるため、人の体に治癒効果をもたらします。

市場動向: 中東およびアフリカの迷走神経刺激市場

ドライバー

• 神経疾患の有病率と発症率の増加

神経疾患は、低所得国でも高所得国でも、すべての疾患の 4.5% ～ 11% の原因となっています。その影響は、悪性腫瘍、胃腸疾患、呼吸器疾患に比べて大きく、今後数年間で拡大すると予想されています。最も一般的な神経疾患の 1 つであるてんかんは、地球上のほぼすべての国に影響を及ぼしています。この疾患の患者のほとんどは、人口の多い国に見られます。この罹患率の上昇により、VNS などのさまざまなツールや治療法の需要が高まっています。より多くの神経疾患が VNS で治療されています。その他の臨床用途に加えて、世界中で神経疾患が著しく蔓延しているため、VNS はてんかんやうつ病などの神経疾患の治療にも役立ちます。

• 需要に応えるために革新的な非侵襲性迷走神経刺激装置を導入

従来の VNS デバイスは患者の体内に埋め込まれ、必要に応じて電気刺激を提供する迷走神経にリードが取り付けられます。革新的なデバイスの需要の高まりと技術の進歩により、小型の埋め込み型 VNS デバイスが市場に導入されるようになりました。これらの小型の埋め込み型デバイスは、患者と医療提供者にさまざまな臨床上の利点をもたらします。革新的なデバイスの導入により、市場の成長が促進されると予想されます。

Constant focus by market players to innovate and launch new products had led to the emergence of non-invasive VNS (nVNS) devices in the market. These devices are also known as transcutaneous VNS (tVNS) devices

• Rise in product approvals

The approval for VNS devices is governed by the U.S. FDA and the EU. The FDA issues a final protocol for filing a Pre-market Approval Application (PMA) or a notice of completion of a Product Development Protocol (PDP).

For instance,

• The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Middle East and Africa, new nVNS devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.

The approval received for VNS devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets, situated in the Middle East and Africa region. Hence, the rise in product approvals is expected to propel market growth.

• Product development in recent years

Combination Therapies are much more effective than monotherapy, without additional side effects. They are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

• Strategic initiatives by the key market players

The demand for VNS devices is increasing in the market owing to the increased levels of R&D; along with that, the market growth is being aided by the desire for innovative medications. Thus, the top market players have implemented new strategies by developing new devices and equipment as well as collaborating with other players in the market and aimed at improving business operations and profitability.

The companies operating Middle East and Africa in this market are adopting collaboration as a strategy to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, increasing strategic initiatives by key market players are expected to offer significant opportunities for market players operating in the market

• Rising government initiatives for neurological disease

The purpose of funding for VNS devices is to encourage applications seeking to develop devices for various neurological disorders. Novel devices should move beyond existing electrical or magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Therefore, the funding by the government would result in the safety of the patient and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence, the advancements in R&D activities and funding by the government will act as an opportunity for this market growth.

Restraint/Challenge

• High maintenance and device costs to restrain adoption of vagus nerve stimulators

The rise in the cost of VNS devices is due to technological development and increased demand for nVNS devices by neurologists in hospitals, clinics, nursing facilities, and ambulatory surgical centers. Overhead costs can help explain why hospitals charge so much for stimulation devices. The increased intricacy and cost of VNS devices, technological innovations, and robust investments would increase the costs. The increased cost would result in delayed treatment of patients in hospitals and clinics. Hence, the increased cost of VNS devices is expected to restrain market growth.

Post-COVID-19 Impact on Middle East and Africa Vagus Nerve Stimulation Market

The COVID-19 outbreak had a drastic effect on Middle East and Africa healthcare with a number of countries severely impacted. The pandemic had a negative impact on the market growth, on account of a temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Development

• In May 2022, electroCore, Inc. announced that the gammaCore Sapphire non-invasive Vagus Nerve Stimulator will be available in 130 National Spine and Pain Centers (NSPC) affiliated locations across the U.S. for patients suffering from pain associated with different forms of primary headache. This would help the organization to develop more revenue.

Middle East and Africa Vagus Nerve Stimulation Market Scope

Middle East and Africa vagus nerve stimulation market is segmented into product type, biomaterial, application, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Implantable VNS Devices
• External VNS Devices

Based on product type, the market is segmented into implantable VNS devices and external VNS devices.

Biomaterial

• Ceramics
• Metallic
• Polymeric

Based on biomaterial, the market is segmented into ceramics, metallic, and polymeric.

Application

• Pain Management
• Epileptic Seizures
• Obesity Management
• Depression and Anxiety
• Others

Based on application, the market is segmented into pain management, epileptic seizures, obesity management, depression and anxiety, and others.

Patient Type

• Adults
• Pediatric
• Geriatric

Based on patient type, the market is segmented into adults, pediatric, and geriatric.

End User

• Hospital
• Ambulatory Surgery Centers
• Specialty Centers
• Others

Based on end user, the market is segmented into hospitals, ambulatory surgery centers, specialty centers, and others.

Distribution Channel

• Direct Tender
• Retail Sales
• Others

Based on distribution channel, the market is segmented into direct tender, retail sales, and others.

Middle East and Africa Vagus Nerve Stimulation Market Regional Analysis/Insights 

The Middle East and Africa vagus nerve stimulation market is analyzed and market size insights and trends are provided by country, product type, biomaterial, application, patient type, end user, and distribution channel as referenced above.

South Africa dominates the Middle East and Africa vagus nerve stimulation market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting market growth.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Vagus Nerve Stimulation Market Share Analysis

The Middle East and Africa vagus nerve stimulation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.

この市場で活動している主要企業としては、Medtronic、LivaNova PLC、electroCore, Inc.、Soterix Medical Inc.、SetPoint Medical、MicroTransponder Inc、Parasym Ltd、tVNS Technologies GmbH などがあります。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、MEA と地域、ベンダー シェア分析が含まれます。さらに質問がある場合は、アナリストへの電話をリクエストしてください。

SKU-69406